https://fis.tu-dresden.de/portal/de/journals/biomedicines(5f3b3257-729c-4eb7-87d3-d8b020fa585f).html
Biomedicines | TU Dresden
tu dresdenbiomedicines
https://remotefirstjobs.com/companies/generate-biomedicines/jobs/associate-director-statistical-programming-768334
Associate Director, Statistical Programming at Generate:Biomedicines
Apply to Associate Director, Statistical Programming hiring by Generate:Biomedicines. Find Remote and Work from Home jobs in Data on Remote First Jobs.
associate directorstatistical programminggenerate biomedicines
https://www.cmlviz.com/stocks/GENB
GENB - Generate Biomedicines Inc Quote, Price, Charts & News - CMLViz.com
GENB Stock Price | Generate Biomedicines Inc(XNAS:GENB) stock summaries, charts and news
generate biomedicinesprice chartsincquotenews
https://www.longdom.com/biotechnology/registration
Registrations | Biotechnology Conferences | Industrial Biotechnology Conferences | Biomedicines...
National Biotechnology Conference. Oct 09-11, 2023, Venue Paris, France, Register Now!
biotechnology conferencesregistrationsindustrialbiomedicines
https://academicworldresearch.org/conference/101011093
National Conference on BioTechnology and BioMedicines | Academic World Research | Academic World...
The aim of the Conference is to provide a platform to the researchers and practitioners from both academia as well as industry to meet the share cuttingedge dev
national conferencebiotechnologybiomedicinesacademicworld
https://biohired.com/jobs/76909
Senior Research Associate/Associate Scientist at Sail Biomedicines in Cambridge, MA | Biohired
research associatecambridge maseniorscientistsail
https://www.talk.bio/2026/04/flagship-pioneering-launches-serif.html
Flagship Pioneering Launches Serif Biomedicines with $50M for DNA Medicines
flagship pioneeringlaunchesserifbiomedicinesdna
https://stocknews.ai/ai-news/generate-biomedicines-inc-reports-first-quarter-2026-financial-results-and-provides-business-update/69fc6c2588d02a4cade20e48
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business...
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advanceClinical trial sites activated for GB-4362 (MMAE neutralizer);...
generate biomedicinesfirst quarterfinancial resultsincreports
https://publicatt.unicatt.it/handle/10807/316496
10th Anniversary of Biomedicines - Advances in Endothelial Dysfunction
endothelial dysfunctionanniversarybiomedicinesadvances
https://www.renaissancecapital.com/Profile/GENB/Generate-Biomedicines/IPO
Generate Biomedicines: GENB IPO, Health Care - Phase 3 biotech using AI to develop therapies for...
IPO: Generate Biomedicines (GENB) - Phase 3 biotech using AI to develop therapies for immunology and oncology. - Health Care - Renaissance Capital
generate biomedicineshealth careusing aiipophase
https://pharmabiz.com/ArticleDetails.aspx?aid=185488&sid=2
Ampersand Biomedicines presents preclinical data on AMP-220, a gut-targeted IL-22 AND-Body...
Ampersand Biomedicines presents preclinical data on AMP-220, a gut-targeted IL-22 AND-Body therapeutic, at AAI 2026
ampersandbiomedicinespresentspreclinicaldata
https://www.sail.bio/
Home - Sail Biomedicines
sailbiomedicines
https://www.biopharmaapac.com/news/80/5678/south-korea-invests-in-generate-biomedicines-through-samsung-to-drive-global-biopharma-innovation-.html
South Korea invests in Generate Biomedicines through Samsung to drive global biopharma innovation.
South Korea invests in Generate Biomedicines through Samsung to drive global biopharma innovation.
south koreagenerate biomedicinesinvestssamsungdrive
https://science.rsu.lv/en/activities/biomedicines-journal-3/
Biomedicines (Journal) - RSU
biomedicinesjournalrsu